Железодефицит в кардиологии – новый подход к старой проблеме?


Ф.Ю. Копылов

Кафедра профилактической и неотложной кардиологии ФППОВ, Первый МГМУ им. И.М. Сеченова, Москва
В последние годы появляется все больше научных работ, посвященных диагностике и лечению железодефицита вне зависимости от наличия анемии у пациентов с сердечно-сосудистыми заболеваниями. В кардиологическую практику этот подход пришел из области нефрологии, т. к. многие диагностические и лечебные подходы к анемии и/или железодефициту изучались у больных хронической почечной недостаточностью и зачастую сопутствующей хронической сердечной недостаточностью. Результатом последних исследований, освещенных в данном обзоре, стала постановка вопроса о признании железодефицита независимым фактором риска ухудшения прогноза больных сердечно-сосудистыми заболеваниями и, соответственно, не зависимой от анемии терапевтической мишенью.

Литература


1. Boyd CM, Leff B, Wolff JL, et al. Informing clinical practice guideline development and implementation: prevalence of coexisting conditions among adults with coronary heart disease. J Am Geriatr Soc 2011;59(5):
797–805.
2. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31(15):1872–80.
3. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111(16):2042–49.4. Anand I, McMurray JJ, Whitmore J, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004;110(2):149–54.
5. O'Meara E, Clayton T, McEntegart MB, et al. CHARM Committees and Investigators. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006;113(7):986–94.
6. Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease Kidney Int 2003;64(Suppl. 87):32–9.
7. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease
and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005;16(11):3403–10.
8. Sullivan JL: Iron and the sex difference in heart disease risk. Lancet 1981;1:1293–94.
a. Weissert S, Flint J, Aggarwal S, et al. Iron Deficiency as the Most Ominous Substrate for Anemia in Patients Undergoing Coronary Artery Bypass Surgery Circulation 2011;124: Abstract17396.
9. Cook JD, Lipschitz DA, Miles LE, et al: Serum ferritin as a measure of iron stores in normal subjects. Am J Clin Nutr 1974;27:681–87.
10. Burt MJ, Halliday JW, Powell LW: Iron and coronary heart disease. BMJ 1993; 307:575–76.
11. Cooper CE: Nitric oxide and iron proteins. Biochim Biophys Acta 1999;1411:290–309.
12. Ponka P. Cellular iron metabolism. Kidney Int 1999; 55(69):S2–S11.
13. Cairo G, Bernuzzi F, Recalcati S. Apreciousmetal: iron, an essential nutrient for all cells. Genes and
Nutrition 2006;1:25–40.
14. Anderson GJ, Vulpe CD. Mammalian iron transport. Cell and Mol Life Sciences 2009;66(20):3241–61.
15. Dallman PR. Iron deficiency: does it matter? J Intern Med 1989;226:367–72.
16. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research
to determine a causal relationship. J Nutr 2001;131:S676–S88.
17. Anker SD, Colet JC, Filippatos G, et al. FAIRHF committees and investigators. Rationale and
design of Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure (FAIRHF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail 2009;11:1084–91.
18. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131(2 Suppl. 2):S568–S79.
19. Weiss G, Goodnough LT. Anemia of Chronic Disease. New Eng J Med 2005;352(10):1011–23.
20. Mastromarino V, Volpe M, Musumeci MB, et al. Erythropoietin and the heart: facts and perspectives. Clin Sci (Lond) 2011; 120(2):51–63.
21. Silverberg DS, Wexler D, Blum M, Iaina A. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clinical Nephrology 2003;60(1):93–102.
22. Silverberg DS, Wexler D, Iaina A, Schwartz D. Correction of iron deficiency in the cardiorenal syndrome. Int J Nephrol 2011;2011:365301.
23. http://www.who.int/vmnis/indicators/serum_ferritin_ru.pdf.
24. Kansagara D, Dyer E, Englander H, Freeman M, Kagen D. Treatment of Anemia in Patients with
Heart Disease: A Systematic Review [Internet]. Washington (DC): Department of Veterans Affairs (US);2011 Oct.
25. http://www.ncbi.nlm.nih.gov/books/NBK83423/pdf/TOC.pdf.
26. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure
and iron deficiency. New England Journal of Medicine 2009;361(25):2436–48.
27. Toblli JE, Lombrana A, Duarte P, Di Gennaro F. Intravenous iron reduces NTpro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. Journal of the American College of Cardiology 2007;50(17):1657–65.
28. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. Journal of the American College of Cardiology 2008;51(2):103–12.
29. Van Wyck DB, Roppolo M, Martinez CO, et al, for the United States Iron Sucrose (Venofer)
Clinical Trials Group: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846–56.
30. Rozen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008;52:897–906.
31. Palazzuoli A., Silverberg D. S., Iovine F. et al. Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. American Heart Journal 2007;154(4): 645e9–5e15.
32. Krum H, Jelinek MV, Stewart S, Sindone A, Atherton JJ. National Heart Foundation of Australia; Cardiac Society of Australia and New Zealand. 2011 update to National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Guidelines for the prevention, detection and management of
chronic heart failure in Australia, 2006. Med J Aust 2011;194(8):405–9.
33. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012;33(14):1787–847.


Об авторах / Для корреспонденции


Копылов Ф.Ю. – Первый МГМУ им. И.М. Сеченова, Кафедра профилактической и неотложной кардиологии ФППОВ, e-mail: cardiolog@inbox.ru


Похожие статьи


Бионика Медиа